From:
$19.11
Prescription required
Amlodipine/valsartan (Exforge): Uses, Dosage, Side Effects, and More
Reviewed by:
From:
$19.11
Prescription required
Amlodipine/valsartan is an oral, fixed-dose combination prescription tablet pairing a dihydropyridine calcium channel blocker (CCB) with a non-heterocyclic angiotensin II receptor blocker (ARB).
Clinically, this combination tablet is indicated for the treatment of hypertension. It is utilized within two primary management frameworks:
- Step-Up Combination Therapy: For patients whose blood pressure is not adequately controlled on amlodipine (or an alternative CCB) alone, or on valsartan (or an alternative ARB) alone.
- Initial Baseline Therapy: For patients requiring multiple agents to achieve intensive blood pressure targets, typically those with baseline blood pressure more than 20/10 mmHg above their specific clinical goal.
By combining two distinct mechanisms of action—inhibiting calcium ion influx into vascular smooth muscle and blocking the renin-angiotensin-aldosterone system (RAAS)—the formulation delivers a synergistic reduction in peripheral vascular resistance. Crucially, the combination also mitigates certain treatment-limiting side effects inherent to CCB monotherapy.
Your Prescription
Ready to Fill
Your savings with us
Avg. price at other pharmacies
Drug Facts
Generic name
Amlodipine/valsartan
Brand names
Exforge
Drug type
Fixed-dose combination antihypertensive; dihydropyridine calcium channel blocker (CCB) and angiotensin II receptor blocker (ARB)
Controlled substance
Not a controlled medication
Dosage forms
Oral film-coated tablets (available strengths: 5 mg/80 mg, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, and 10 mg/320 mg)
Typical dosage
Adults typically take one tablet by mouth once daily, with or without food. The starting dose depends on the patient’s blood pressure control and previous antihypertensive treatment. Dosage may be adjusted after 1–2 weeks if necessary. The maximum recommended dose is 10 mg/320 mg once daily. Tablets should be taken at approximately the same time each day and swallowed whole.
Mechanism
Mechanism of Action and Pharmacokinetics
Pharmacodynamics and Vasodilatory Synergy
The two active components target peripheral vascular resistance through completely independent, highly complementary physiological pathways:
- Amlodipine Besylate: Amlodipine is a long-acting dihydropyridine calcium channel blocker. It binds selectively to L-type voltage-gated calcium channels on vascular smooth muscle cells, inhibiting the influx of extracellular calcium ions during membrane depolarization. This directly decreases intracellular calcium availability, halting smooth muscle contraction and driving widespread peripheral arterial vasodilation.
- Valsartan: Valsartan functions as a potent, highly selective, and non-competitive antagonist at the angiotensin II type 1 ($AT_1$) receptor site. Physically blocking angiotensin II from binding to $AT_1$ receptors in vascular smooth muscle and the adrenal cortex prevents vasoconstriction and blocks aldosterone synthesis.
The Peripheral Edema Neutralization Phenomenon
A common, dose-dependent side effect of amlodipine monotherapy is the development of peripheral ankle edema. This occurs because CCBs cause potent dilation of the afferent arterioles leading into the capillary beds, without dilating the efferent venules. This uncoupling elevates local capillary hydrostatic pressure, forcing fluid into the surrounding interstitial tissue.
When paired with valsartan, the ARB component induces balanced dilation of both the afferent and efferent vascular beds. This restores homeostatic capillary pressure, significantly reducing the incidence and severity of fluid leakage compared to taking high-dose amlodipine alone.
Pharmacokinetics
- Absorption: Following oral administration, both components are absorbed adequately, reaching peak plasma concentrations ($T_{max}$) within 6 to 12 hours for amlodipine and 2 to 4 hours for valsartan. The absolute bioavailability is roughly 64% for amlodipine and 25% for valsartan. Absorption kinetics are entirely unaffected by food.
- Distribution & Metabolism: Both drugs are heavily protein-bound (greater than 95% to 99%). Amlodipine undergoes slow, comprehensive hepatic metabolism via the CYP3A4 pathway into inactive metabolites. Valsartan does not significantly utilize the Cytochrome P450 system; it is cleared without primary CYP interactions.
- Elimination: Amlodipine displays a prolonged terminal elimination half-life of 30 to 50 hours, supporting smooth, 24-hour baseline control. Valsartan exhibits a half-life of approximately 6 hours. Amlodipine metabolites are excreted primarily in the urine, while valsartan is cleared unchanged via both renal filtration (~30%) and biliary-fecal elimination (~70%).
Dosage
Dosages and Administration
Standard Adult Titration Protocol
- Hypertension Management: One tablet orally once daily, independent of food intake.
- Titration Cadence: Dosing steps should be separated by 1 to 2 weeks of continuous therapy to allow steady-state plasma profiles to fully stabilize and manifest their maximal blood pressure-lowering effect.
- Maximum Dosing Ceiling: The maximum allowable daily dose is 10 mg / 320 mg once daily. Doses must never exceed this boundary.
Strict Dosing Adjustments for Special Risk Groups
- Hepatic Immunological Modifications: Amlodipine and valsartan are extensively cleared via hepatic and biliary pathways. This combination tablet is not recommended for initial baseline therapy in patients with moderate-to-severe hepatic impairment, as the fixed configurations prevent the required low-dose amlodipine baseline initiation (typically 2.5 mg).
- Renal Impairment Constraints: No automatic dose shifts are required for patients with mild-to-moderate renal decline. However, in patients with advanced, severe renal impairment (calculated Creatinine Clearance less than 30 mL/min), closely monitor serum creatinine and potassium levels.
Get The Right Dose For Less
Why pay retail prices for the same medication?
At Invictus, we source directly from trusted, FDA-approved manufacturers to keep your costs low without sacrificing quality. Whether you need a one-time fill or regular refills, our transparent pricing makes it easy to save every day.
Side Effects
Side Effects, Risks, and Safety Warnings
Boxed Warning: Fetal Toxicity
Drugs that act directly on the renin-angiotensin system can cause serious injury, developmental abnormalities, and death to the developing fetus.
- Contraindications: Amlodipine/valsartan is strictly contraindicated during pregnancy.
- Clinical Mandatory Action: When pregnancy is detected, this combination medication must be discontinued immediately. Exposure to ARBs during the second and third trimesters is linked to fetal oligohydramnios (profoundly low amniotic fluid), which can induce fetal cranial hypoplasia, limb contractures, pulmonary hypoplasia, neonatal hypotension, and irreversible fetal death.
Severe Hypotension and Volume Depletion
In patients with an activated renin-angiotensin system—such as individuals with severe volume depletion or hyponatremia secondary to high-dose diuretic therapy, strict dietary salt restriction, or persistent vomiting and diarrhea—initiating this tablet can trigger symptomatic, acute hypotension, syncope, or myocardial hypoperfusion. Volume and electrolyte deficits must be fully corrected before administering the first dose.
Impaired Renal Function and Accelerated Azotemia
Inhibiting the RAAS pathway can cause predictable declines in renal perfusion pressure. In patients whose renal function relies heavily on the activity of the renin-angiotensin-aldosterone axis (e.g., individuals with severe congestive heart failure or bilateral renal artery stenosis), treatment with valsartan can precipitate acute oliguria, progressive azotemia, and acute kidney injury (AKI). Serum creatinine, blood urea nitrogen (BUN), and potassium levels must be monitored regularly.
Common Adverse Reactions
The most frequent side effects documented across large-scale clinical registries are typically mild and dose-dependent:
- Peripheral edema (fluid retention in the lower extremities)
- Dizziness and lightheadedness (including orthostatic effects)
- Flushing and sudden facial warmth
- Headache
- Nasopharyngitis or upper respiratory tract symptoms
- Nausea
Interactions
Critical Drug Interactions
- Strong CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin): Co-administration blocks the primary hepatic breakdown of the amlodipine component, significantly increasing its systemic concentration ($AUC$) and intensifying vasodilatory side effects (severe flushing, edema, hypotension). Monitor closely.
- Dual RAAS Blockade (ACE Inhibitors, Aliskiren): Combining this tablet with an ACE inhibitor (such as lisinopril) or a direct renin inhibitor (such as aliskiren) is strictly discouraged. Dual blockade of the RAAS pathway multiplies the risks of severe hypotension, syncope, hyperkalemia, and acute renal failure without offering additive clinical utility.
- Lithium Toxicity: ARBs reduce the renal clearance and tubular excretion of lithium. Co-administration can rapidly drive serum lithium concentrations into dangerous, toxic ranges. If concurrent use is unavoidable, frequent serum lithium level monitoring is mandatory.
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant use of NSAIDs (such as ibuprofen or naproxen) can blunt the antihypertensive efficacy by inhibiting prostaglandin-mediated vasodilation. Furthermore, in elderly or volume-depleted patients, combining an ARB with an NSAID can cause severe reductions in renal blood flow, triggering acute kidney injury.
Special Populations
Pregnancy and Lactation
- Pregnancy: Strictly contraindicated due to the severe Boxed Warning for embryo-fetal toxicity.
- Lactation: Amlodipine is excreted into human breast milk in low quantities; it is unknown whether valsartan passes into milk, though transfer has been verified in animal matrices. Because of the potential for neonatal hypotension and renal vulnerability, use is generally not recommended during breastfeeding.
Geriatric Care
Older adults aged 65 and over exhibit a significantly higher susceptibility to drug-induced renal decline, advanced orthostatic hypotension, and prolonged amlodipine retention due to age-related hepatic clearance drops. Dosing selection should be highly conservative, typically starting at the lowest available combination strength (5 mg / 160 mg), and closely monitored with routine serum chemistry panels.
Ready to Start Saving?
No one should overpay for safe, effective medication. By cutting out middlemen and working directly with trusted, FDA-approved manufacturers, Invictus offers the same high-quality medicines you’d find at big retail pharmacies—at a fraction of the price.
Whether you choose brand-name or generic, we’ll deliver it quickly, affordably, and right to your door. Maybe that’s why most patients who switch to Invictus never look back.
Frequently Asked Questions (FAQs)
Didn’t see the answers you’re looking for in this article? Check out this comprehensive FAQ for more details.
Administration & Dosage
Amlodipine and valsartan tablets can be taken once daily at any time of day, with or without food — neither component's absorption is significantly affected by meals. Consistency matters more than the specific time chosen: taking the tablet at the same time each day maintains stable blood levels of both amlodipine and valsartan and supports consistent 24-hour blood pressure control. Many patients choose morning dosing as a practical anchor to a daily routine, though evening dosing is equally appropriate. Never stop the combination independently — blood pressure can rise rapidly after discontinuation, and any changes must be made in consultation with your prescribing provider.
Amlodipine begins lowering blood pressure within hours of the first dose, though the full antihypertensive effect of both amlodipine and valsartan at a stable dose typically takes one to two weeks to fully establish. The long half-life of amlodipine means it takes several days of consistent dosing to reach steady-state blood levels, after which blood pressure control becomes more uniform throughout the 24-hour period. Your provider will assess your response at follow-up visits and may adjust the combination strength if the initial response is insufficient. Do not increase your dose independently if you feel the medication is not working quickly enough.
At the standard 5 mg dose, amlodipine typically reduces systolic blood pressure by approximately 8 to 10 mmHg on average, though individual response varies considerably based on baseline pressure, age, and concurrent medications. At 10 mg, reductions of 12 to 15 mmHg systolic are more typical. The valsartan component contributes additional blood pressure lowering through its complementary ARB mechanism — the combined effect of both agents together is meaningfully greater than either component alone. The full sustained reduction at a given dose is established over one to two weeks of consistent daily use rather than immediately after the first dose.
Amlodipine has an exceptionally long plasma half-life of approximately 30 to 50 hours — among the longest of any antihypertensive — meaning it takes about six to seven days of once-daily dosing to reach steady-state blood levels. After stopping, meaningful drug levels persist for several days before the medication fully clears. Valsartan has a much shorter half-life of approximately six hours, but its antihypertensive effect is maintained with once-daily dosing through sustained receptor blockade. The long half-life of the amlodipine component provides smooth, consistent blood pressure control throughout the dosing interval with minimal peak-to-trough variation.
Amlodipine and valsartan combination tablets should not be cut, crushed, or chewed unless your pharmacist confirms that your specific tablet is scored and approved for splitting. Splitting an unscored combination tablet risks uneven distribution of both active ingredients between the two halves, potentially delivering inconsistent doses of amlodipine and valsartan. If dose adjustment is needed, your provider will typically prescribe the appropriate lower-dose tablet rather than directing splitting of a higher-strength tablet. Confirm with your pharmacist before attempting to split any combination antihypertensive tablet.
Take a missed dose as soon as you remember — unless it is almost time for your next dose, in which case skip the missed dose and resume your regular schedule without doubling up. Consistent once-daily dosing is important for sustained blood pressure control, as missed doses allow pressure to rise and undermine the long-term cardiovascular protection this combination is intended to provide. Frequent missed doses can destabilize blood pressure in ways that are not immediately symptomatic but carry cumulative cardiovascular risk. If adherence is consistently difficult, discuss this with your provider or pharmacist.
Uses & Mechanism of Action
Amlodipine and valsartan tablets are used to treat hypertension in adults whose blood pressure is not adequately controlled on either agent alone. The combination pairs a calcium channel blocker with an angiotensin II receptor blocker to lower blood pressure through two distinct and complementary mechanisms, producing greater reductions than typically achievable with monotherapy at equivalent doses. The combination is indicated for patients who require dual antihypertensive therapy and is not appropriate as a first-line treatment for patients who have not yet tried either component individually.
Amlodipine is a long-acting dihydropyridine calcium channel blocker — the vasodilatory component of this combination tablet. It is the same molecule whether described as amlodipine, amlodipine besylate, or the brand name Norvasc — besylate refers only to the salt form used in manufacturing and does not affect pharmacological activity. Amlodipine is not a beta blocker, not a diuretic, and not a water pill — it lowers blood pressure by relaxing blood vessel walls rather than by reducing heart rate or increasing fluid excretion. It belongs to the same calcium channel blocker class as nifedipine and felodipine.
Valsartan is an angiotensin II receptor blocker — the RAAS-targeting component of this combination. It is not a beta blocker, not a statin, and not a diuretic. Valsartan lowers blood pressure by blocking the action of angiotensin II at the AT1 receptor, preventing vasoconstriction and aldosterone-stimulated sodium and water retention. It is the same active ingredient found in the standalone brand Diovan. In the combination tablet, valsartan contributes blood pressure reduction through a mechanism entirely distinct from amlodipine, which is why the two agents work additively when combined.
Amlodipine lowers blood pressure by blocking L-type calcium channels in the smooth muscle cells of peripheral blood vessel walls. Calcium influx through these channels is required for smooth muscle contraction — by blocking this entry, amlodipine prevents vasoconstriction and causes sustained peripheral vasodilation, reducing vascular resistance. This occurs without primarily affecting heart rate, distinguishing it from beta blockers and non-dihydropyridine calcium channel blockers. Amlodipine's gradual onset and long duration of action produce smooth, sustained blood pressure lowering with minimal reflex cardiovascular effects compared to shorter-acting agents in the same class.
Valsartan lowers blood pressure by selectively blocking the angiotensin II type 1 receptor — through which angiotensin II drives vasoconstriction and aldosterone-stimulated sodium and water retention. By blocking these effects, valsartan causes vasodilation and reduces fluid volume. This mechanism addresses RAAS-driven hypertension from a fundamentally different angle than amlodipine's calcium channel blockade, targeting neurohormonal vasoconstriction rather than vascular smooth muscle directly. The complementary nature of these two mechanisms is what makes the combination particularly effective in patients with multifactorial hypertension.
Side Effects & Safety
The most commonly reported side effects of amlodipine and valsartan include peripheral edema — swelling of the ankles and feet — attributable to the amlodipine component and reflecting vasodilation rather than fluid retention from kidney dysfunction. Dizziness and lightheadedness, particularly upon standing, are also common when starting treatment or increasing the dose. Headache and flushing are reported with amlodipine. Valsartan-related effects include dizziness and modest creatinine or potassium rises reflecting its ARB hemodynamic effects on the kidney. These effects are generally mild and often improve at a stable dose.
The most clinically serious adverse effects of amlodipine include severe hypotension — particularly in volume-depleted patients or those on multiple antihypertensives — and worsening of angina or myocardial infarction on initiation in patients with obstructive coronary artery disease. Peripheral edema can become severe enough to require dose reduction or discontinuation in some patients. The valsartan component adds its own serious risks — most critically embryo-fetal toxicity, which makes the combination absolutely contraindicated during pregnancy, and hyperkalemia or acute kidney injury in susceptible patients. Any sudden worsening of chest pain, significant leg swelling, or pronounced dizziness after starting this combination warrants prompt medical evaluation.
Amlodipine does not meaningfully lower heart rate in most patients. Unlike non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, which act on cardiac conduction tissue, amlodipine acts selectively on peripheral vascular smooth muscle. Some patients notice a very modest reflex heart rate increase early in treatment as blood pressure falls and baroreceptors compensate, though this is minimal given amlodipine's gradual onset. Valsartan similarly has no significant direct effect on heart rate. If heart rate reduction is a clinical goal alongside blood pressure control, your provider may consider adding a beta blocker to the regimen.
Amlodipine does not increase urinary frequency — it is not a diuretic, does not contain a diuretic, and has no mechanism that increases urine production. It lowers blood pressure exclusively by relaxing blood vessel walls, with no effect on renal sodium or water handling. Valsartan also has no significant diuretic effect, though it modestly reduces aldosterone levels, affecting sodium handling. If you experience increased urination after starting this combination, other causes — including diabetes, a concurrent medication, or changes in fluid intake — are more likely responsible and should be discussed with your provider.
Valsartan is not associated with weight gain as a pharmacological effect — ARBs do not cause fat accumulation, appetite stimulation, or the metabolic changes that drive weight gain with agents such as corticosteroids or certain antidepressants. Amlodipine can cause peripheral edema — fluid accumulation in the lower limbs — which may appear as a modest increase on the scale without representing true fat gain. If you notice significant weight gain after starting this combination, distinguishing fluid-related weight change from other causes is important. Rapid or substantial weight gain accompanied by increased leg swelling and shortness of breath warrants prompt medical evaluation.
Dry mouth is a recognized but uncommon side effect of amlodipine, appearing in post-marketing reports rather than as a frequently documented adverse event in clinical trials. The mechanism is thought to relate to the effect of calcium channel blockade on salivary gland function in some patients. Staying well hydrated and using saliva substitutes can help manage this symptom if it occurs. Persistent or severe dry mouth should be discussed with your provider, who can assess whether it is related to the medication and whether any adjustment is warranted.
Interactions & Contraindications
Amlodipine and valsartan are absolutely contraindicated during pregnancy — the valsartan ARB component carries an FDA boxed warning for embryo-fetal toxicity, causing severe fetal renal dysplasia, oligohydramnios, and neonatal death when used in the second or third trimester. Women of reproductive potential must use effective contraception and stop the combination immediately if pregnancy occurs. Patients with known hypersensitivity to either component are contraindicated. Amlodipine should be avoided in severe aortic stenosis. Valsartan is contraindicated with aliskiren in diabetic patients. Severe hepatic impairment requires dose assessment for both components.
Amlodipine is metabolized by CYP3A4 — strong inhibitors including ketoconazole, itraconazole, clarithromycin, and ritonavir can significantly increase amlodipine levels, causing excessive blood pressure lowering. CYP3A4 inducers such as rifampin can reduce amlodipine efficacy. Valsartan interactions center on potassium: ACE inhibitors, other ARBs, potassium-sparing diuretics, and potassium supplements increase hyperkalemia risk. NSAIDs reduce the antihypertensive effect of valsartan and can worsen kidney function. Lithium levels may be raised by the valsartan component. Always provide a complete medication list to your prescriber and pharmacist before starting this combination.
Valsartan's ARB mechanism can be nephroprotective in patients with chronic kidney disease — particularly those with diabetic nephropathy and proteinuria — by reducing intraglomerular hypertension. A modest creatinine rise of up to 30% after starting is generally considered acceptable. Significant renal impairment increases hyperkalemia risk with valsartan and warrants closer monitoring. Amlodipine does not require dose adjustment in kidney disease as it is hepatically eliminated. The combination can be used in many CKD patients under appropriate monitoring, though severe renal impairment warrants specialist nephrology involvement in managing the overall antihypertensive regimen.
Amlodipine and valsartan must not be used during pregnancy. The valsartan component carries an FDA boxed warning — ARB exposure in the second and third trimesters causes fetal renal dysplasia, oligohydramnios leading to limb contractures and pulmonary hypoplasia, and neonatal renal failure. Even first-trimester ARB exposure should be avoided where possible. Women who become pregnant while taking this combination must contact their provider immediately to transition to a pregnancy-safe antihypertensive such as methyldopa, labetalol, or nifedipine. Effective contraception is required throughout treatment for all women of reproductive potential.
Generic & Alternatives
The brand name Exforge refers to the amlodipine and valsartan combination tablet, and the generic name is amlodipine and valsartan. Generic amlodipine/valsartan combination tablets are available in the United States in multiple strength combinations — expressed as amlodipine mg/valsartan mg — and are considered bioequivalent to brand-name Exforge by the FDA. Amlodipine besylate is the salt form of amlodipine used in the tablet and is pharmacologically identical to amlodipine — the two terms refer to the same active compound. Your pharmacist can confirm current generic availability.
Yes — amlodipine besylate and amlodipine are the same active drug. Besylate refers to the benzenesulfonate salt form used to stabilize the amlodipine molecule in tablet form and has no pharmacological activity of its own. Once absorbed, amlodipine besylate releases free amlodipine, which produces the blood pressure-lowering effect. All clinical evidence and dosing for amlodipine applies equally to amlodipine besylate — they are interchangeable terms describing the same medication and should not be treated as different drugs when reading prescribing information or clinical studies.
Several alternative combination antihypertensive products pair a calcium channel blocker with an ARB. Amlodipine and olmesartan (Azor), amlodipine and telmisartan (Twynsta), and amlodipine and irbesartan offer the same dual CCB-plus-ARB mechanism with different ARB components. For patients where a different combination class is preferred, ARB-plus-thiazide combinations — such as valsartan-HCTZ — provide an alternative pairing strategy. ACE inhibitor-based combinations are an option for patients without prior ARB-specific indications, though they carry the risk of persistent dry cough. Your provider will recommend the most appropriate combination based on your blood pressure pattern, comorbidities, and tolerability history.
Valsartan is an angiotensin II receptor blocker and is not related to the beta blocker drug class. Beta blockers — such as metoprolol, atenolol, and carvedilol — lower blood pressure by blocking adrenergic receptors on the heart and blood vessels, reducing heart rate and cardiac output. Valsartan works through a completely different mechanism, blocking the AT1 receptor through which angiotensin II drives vasoconstriction and fluid retention. Valsartan is also not a statin, not a diuretic, and not a calcium channel blocker. Understanding the distinction matters clinically — unlike beta blockers, valsartan does not lower heart rate and is not used for rate control in arrhythmias.
Disclaimer
The information provided on this page is for general informational purposes only and is not intended as medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication regimen. While Invictus strives to provide accurate and up-to-date information, individual health conditions and circumstances vary. The prices, availability, and descriptions of all medications on this page are subject to change.
Your Prescription
Ready to Fill
Your savings with us
Avg. price at other pharmacies
